Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer: The Hunt for the Silver Bullet

At the American Society for Radiation Oncology annual meeting in 2014 in San Francisco, significant excitement rose from a genitourinary oral session in which several abstracts discussed the potential for localized treatment of N1 prostate cancer to change anticipated survival outcomes (1-3). Since then, studies have been published on the utility of treatment for both N1 and true metastatic disease, arguing that prevention of "reseeding" from primary disease or current metastases can reduce future metastases (4).

http://ift.tt/2zuklEP